However, ICI efficacy is inconsistent in osteosarcoma, likely due to its low tumor mutational burden (TMB) and heterogeneous PD-L1 expression, limiting neoantigen availability and immune recognition (82, 83). The gene discussed is CD274; the disease is osteosarcoma.